Sort by
Medicine and Dentistry
Adverse Event
6%
Anemia
16%
Bevacizumab
25%
Biological Marker
11%
Blood Sampling
16%
Cancer Cell
8%
Cervical Cancer
36%
Cervicectomy
50%
Chemotherapy
10%
Clear Cell Carcinoma
25%
Clinical Feature
25%
DNA Damage
25%
Fatality
6%
Homologous Recombination
14%
Hormone Determination
21%
Hypoxia
8%
Infusion
7%
Interleukin 33
25%
Lanatoside C
7%
Lymph Node Metastasis
25%
Lymphocyte
25%
Lymphoid Cell
6%
Maintenance Therapy
14%
Malignant Ascites
25%
Mean Platelet Volume
25%
Mesenchymal-Epithelial Transition
25%
Metastatic Carcinoma
8%
Minimally Invasive Procedure
25%
Nausea
10%
Neutrophil
8%
Niraparib
37%
Obstetrics
25%
Olaparib
50%
Ovarian Cancer
50%
Ovarian Reserve
25%
Overall Survival
15%
Paracentesis
22%
PARP Inhibitor
50%
Progression Free Survival
9%
Prospective Study
25%
Recurrent Disease
13%
Recurrent Ovarian Cancer
25%
Retrospective Study
10%
Safety Assessment
25%
Serous Carcinoma
14%
Tertiary Lymphoid Structure
12%
Thrombocytopenia
16%
Treatment Interruption
10%
Uncoupling Protein 2
25%
Uterine Cancer
50%
Keyphrases
Adverse Events
5%
Anti-Mllerian Hormone
21%
Bevacizumab
25%
Bevacizumab Therapy
20%
Blood Data
8%
Blood Toxicity
6%
Cancer Center
5%
Controlled Ovarian Stimulation
6%
Conventional Chemotherapy
10%
DDIT4
25%
Desert
9%
Digital Analysis
12%
DNA Damage-inducible Transcript 4
25%
Epithelial Ovarian Cancer
10%
Half-dose
10%
Heavily Treated
25%
High-grade Serous Carcinoma
8%
Homologous Recombination Deficiency
8%
Hormone Levels
21%
Informed Consent
5%
Inhibitor Response
25%
Japanese Patients
25%
Lanatoside C
7%
Let-7 Family
25%
Maintenance Therapy
8%
Malignant Ascites
25%
Mean Platelet Volume
25%
Medical Expenses
5%
Neutrophil Count
8%
Niraparib
12%
Non-responders
8%
Olaparib
25%
Ovarian Cancer
30%
Ovarian Clear Cell Carcinoma
25%
Ovarian Reserve
25%
Palliative Approach
10%
Paracentesis
15%
PARP Inhibitor (PARPi)
25%
Penalized Regression
25%
Performance Prediction
8%
Peritumoral Lymphocytes
25%
POLE mutation
6%
Potential Biomarkers
25%
Progressive Disease
5%
Radical Trachelectomy
25%
Random Forest Regression
8%
Recurrent Ovarian Cancer
25%
Small EVs
25%
Survival Outcomes
25%
Vaccinia-related Kinase
25%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
6%
Anemia
16%
Aubergine
6%
Bevacizumab
25%
Biological Marker
8%
Blood Toxicity
6%
Carcinoma
14%
Clinical Feature
25%
Disease
8%
Female Genital Tract Cancer
5%
Interleukin 33
25%
Lanatoside C
7%
Malignant Ascites
25%
microRNA
25%
Nanoparticle
5%
Nausea
10%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
50%
Niraparib
37%
Olaparib
50%
Ovary Cancer
100%
Recurrent Disease
10%
Retrospective Study
10%
Safety Assessment
25%
Therapeutic Effect
5%
Thrombocytopenia
16%
Vaccinia
25%
Western Blot
5%
